November 25th 2020
Milind Javle, MD, provides insight into the current treatment paradigm of advanced HCC and the potential influence ongoing research regarding biomarkers of response and novel combinations could have on the field.
November 24th 2020
Alan P. Z. Skarbnik, MD, highlights how treatment decisions in mantle cell lymphoma have become more nuanced since the FDA approval of the CAR T-cell therapy brexucabtagene autoleucel in the relapsed/refractory setting.
November 22nd 2020
Sotorasib was well tolerated and led to disease control in the majority of patients with heavily pretreated KRAS G12C–mutant gastrointestinal malignancies.
November 20th 2020
The noninvasive blood-based targeted methylation assay ELSA-seq identified early cancers with high specificity and provided accurate predictions of the tissue of origin.
November 17th 2020
November 17, 2020 — The 11th Annual Ruesch Center Symposium, taking place virtually on November 20 to 21, 2020, will feature sessions that span innovations in gastrointestinal cancer, advances in nuclear imaging and therapy for neuroendocrine tumors, precision oncology web educational resource, and patient symposia, bringing participants together in a forum for discussion, networking, and debate on pressing issues in the field.
November 13th 2020
November 13, 2020 – The addition of urelumab, an anti-CD137 agonist to the GVAX vaccine and nivolumab led to a 30% pathologic response rate and was associated with mild toxicity as neoadjuvant or adjuvant therapy in patients with resectable pancreatic ductal adenocarcinoma.
November 13th 2020
November 13, 2020 - The genetically modified herpes simplex-1 oncolytic RP2 demonstrated encouraging clinical activity and an acceptable safety profile in heavily pretreated patients with advanced solid tumors
November 12th 2020
November 12, 2020 - Cemiplimab demonstrated clinically meaningful antitumor activity, including durable responses, and acceptable safety in patients with metastatic basal cell carcinoma after progression on or intolerance to hedgehog inhibitors
November 11th 2020
November 11, 2020 - Rao Mushtaq, MD, provides perspective on these pivotal data in EGFR-mutant non–small cell lung cancer.